«

»

Payers await Medicare preliminary decision on Aduhelm coverage

Biogen slashed the price of its controversial Alzheimer's drug Aduhelm after a problematic  rollout, but the move has still done little to encourage Medicare to cover the controversial drug.

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive